To develop a set of prescribing indicators measurable with available data from electronic nursing home (NH) databases by adapting the European-based 2014 Screening Tool of Older Person's Prescriptions (STOPP) and Screening Tools to Alert Doctors to Right Treatment (START) criteria of potentially inappropriate and underused medications for the U.S. setting. DESIGN: A two-stage expert panel process. In the first stage, the investigator team reviewed 114 criteria for compatibility and measurability. In the second stage, an online modified e-Delphi (OMD) panel was convened to rate the validity of criteria, and two webinars were held to identify criteria with highest relevance to U.S. NHs. PARTICIPANTS: Seventeen experts with recognized reputations in NH care participated in the e-Delphi panel and 12 in the webinar. MEASUREMENTS: Compatibility and measurability were assessed by comparing criteria with U.S. terminology and setting standards and data elements in NH databases. Validity was rated using a 9-point Likert-type scale (1 = not valid at all, 9 = highly valid). Mean, median, interpercentile ranges, and agreement were determined for each criterion score. Relevance was determined by ranking the mean panel ratings on criteria that reached agreement; the webinar participants reviewed and approved half of the criteria with the highest mean values. RESULTS: Fifty-three STOPP/START criteria were deemed to be compatible with the U.S. NH setting and measurable using data from electronic NH databases. E-Delphi panelists rated 48 criteria as valid for U.S. NHs. Twenty-four criteria were deemed to be most relevant, consisting of 22 measures of potentially inappropriate medications and two measures of underused medications. CONCLUSION: This study created the first explicit criteria for assessing the quality of prescribing in U.S. NHs. J Am Geriatr Soc 65:586-591, 2017.
N early 3.2 million elderly and disabled Americans receive care in nursing homes (NHs) each year. On average, NH residents who remain for longer than a short stay (>90 days) receive 10 different medications per month, 1, 2 but the overall quality of prescribing in NHs is unclear; high use of medications in NHs may include overuse of suboptimal medications but does not preclude the underuse of beneficial medications. Nearly 60% of NH residents receive unnecessary medications, whereas the underuse of beneficial medications may be as high as 42%. 3 Living in a NH is an independent predictor of underprescribing, 4 and at least 16 studies have demonstrated underprescribing in NHs in the context of specific conditions. [5] [6] [7] Underuse or overuse of clinically indicated drug therapies has been associated with morbidity, mortality, and poor quality of life in NHs. 8 A critical barrier to assessing the quality of prescribing in NHs has been the lack of explicit criteria for the NH population, particularly the majority who are frail and elderly. Most tools for assessing inappropriate prescribing are developed for older adults living in the community, and few consider the underuse of beneficial medications. The Screening Tool of Older Person's Prescriptions (STOPP) is a validated, evidence-based list of 80 criteria for potentially inappropriate prescribing in communitydwelling older adults. 9, 10 The Screening Tools to Alert Doctors to Right Treatment (START) is a set of 34 evidence-based and validated prescribing indicators for common diseases in community-dwelling older adults. 9, 10 More than 45 research studies have used the STOPP/ START criteria since they was made available. 3 The criteria were developed to improve quality of care and are widely used in Europe but, to the knowledge of the authors of the current study, have not been adapted to the U.S. NH population. 11 There are other criteria, including the Beers criteria of potentially inappropriate medications in elderly adults, but to the authors' knowledge, only the STOPP/START criteria address underprescribing of medications. 12 Developers of the STOPP/START criteria have concluded that it is possible to apply them in NHs, but some indicators may "have limited practical value, given that life expectancy is short." 3 The primary objective of this study was to adapt the STOPP/START criteria for the U.S. NH setting using an e-Delphi consensus panel. A secondary aim was to create a broadly useful subset of STOPP/START prescribing indicators that could be measured with information captured in widely used electronic NH databases. NHs participating in Medicare and Medicaid are required to assess a core set of data elements on all nursing home residents called the Minimum Data Set. 13 The work presented here is part of a larger investigation sponsored by the National Institutes of Health (R01AG046341) to investigate the relationship between Medicare Part D prescription drug coverage and medication use in NHs.
METHODS

STOPP and START Criteria
The STOPP/START criteria were originally developed in Ireland after a review of the evidence base of systematic reviews and randomized clinical trials on best prescribing practices for community-dwelling older adults. The criteria were updated in 2014, which is the version used in this study. 14 The materials for the Delphi panel were prepared in two phases. In Phase 1, an investigative team consisting of the principal investigator (BB), two pharmacists (CB, BJZ), and a geriatrician (MP) reviewed each of the 114 2014 STOPP/START criteria for compatibility and measurability in the context of the U.S. setting and NH populations. This process included modifying text to American terminology, deleting references to drugs that were not available in the U.S. market, simplifying conditional qualifiers that were deemed to be less relevant in NH setting, and making some general criteria more targeted in scope (Table S1 ). For example, the term "neuroleptics" was replaced with "antipsychotics," a criterion about maintenance therapy was redefined as therapy exceeding 14 days, and the criterion for any duplicative therapy was limited to duplicative therapy in four drug classes (hypnotic-sedatives, antidepressants, antipsychotics, anxiolytics). In this stage, the measurability of each criterion was also assessed using the standard data elements available in the Minimum Data Set 3.0, Medicare Part A and B claims, and pharmacy dispensing records. Criteria that depended on laboratory values or medical histories were deemed not to be measurable in these data.
Panel Selection
In Phase 2, an e-Delphi panel was conducted. Twenty-two experts with recognized reputations in NH care and interdisciplinary skills representing geriatric medicine, nursing, clinical pharmacy, research, policy, and quality assurance were invited. Other selection criteria included clinical knowledge of NH prescribing and active role in caring for NH residents. Individuals indicating interest were asked to provide explicit consent to participate in the study and basic demographic and professional information. A $250 honorarium was offered for participation. The Human Subjects Protection Committee at RAND determined that these activities were exempt from review; the institutional review board at Northeastern University approved the overall study.
E-Delphi Panel
The expert panel was conducted using an online platform (ExpertLens) 15, 16 to identify the most-valid STOPP/START criteria for the U.S. NH setting. The Delphi method is a well-established, structured approach for soliciting the opinions of experts and establishing a convergence of opinion. 17 Although the e-Delphi panel has not been formally compared with its face-to-face counterpart, it has been deemed acceptable for developing health services performance measures 18 and has been shown to provide a useful and feasible forum for allowing participants on an expert panel to provide ratings and take part in moderated on-line discussions that produce replicable results. 16 This e-Delphi platform has been successfully used in numerous studies on healthcare topics. [18] [19] [20] [21] [22] [23] Before the e-Delphi panel was held, the protocol was drafted and pilot tested to isolate programming or formatting problems and to finalize instructions and question phrasing. After the pilot, STOPP/START criteria examples were developed and added to the protocol to better justify and explain their meaning in the U.S. NH context ( Figure S1 ).
The e-Delphi panel consisted of three rounds: initial assessment, feedback and discussion, final assessment. Login and participation training were conducted through online videos. In Round 1, participants rated the validity of the 52 STOPP/START criteria deemed compatible and measurable in Phase 1 of this study (Table S1 , column 3) on a 9-point Likert-type scale (1 = not valid at all, 9 = highly valid). For each criterion, participants were asked to consider whether there is adequate scientific evidence or professional consensus to support the criterion in the NH population and whether there are clear health benefits to NH residents who receive care specified according to the criterion. Participants were asked to explain their numeric response using an open-text box displayed below each question. Round 1 was open September 1 to 18, 2015.
In Round 2, the experts received an individualized summary of Round 1 results. Each participant saw a series of bar charts showing the frequency distributions of responses to all Round 1 questions. On each chart, they saw their own rating, the group median rating, and the interquartile range of group responses. They also saw and commented on all rating explanations provided in Round 1. Finally, they could anonymously participate in an asynchronous discussion about the validity of each criterion; the principal investigator, who posted probing questions about unclear or discordant ratings, moderated this online discussion. Round 2 was open September 18 to 28, 2015.
In Round 3, experts were encouraged to revise their Round 1 ratings in light of Round 2 group feedback and discussion. Criteria deemed invalid or of uncertain validity in Round 1 (see below) were rerated in Round 3. Round 3 was open September 28 to October 9, 2015.
Finally, after the e-Delphi process concluded, two webinars were conducted to address comments generated throughout the e-Delphi process indicating concerns that some criteria were clinically valid but less relevant to a NH population of older adults. For example, the criterion "prescription of disease-modifying antirheumatic drugs for rheumatoid arthritis" was rated as valid, but the accompanying comments indicated that this would be a rare problem in NH setting.
During the first webinar, e-Delphi participants adjudicated the criteria with uncertain validity. During the second webinar, they discussed the relevance of the criteria deemed valid during the e-Delphi process in the context of a typical case scenario in the U.S. NH setting. 24 
Data Analysis
The final validity rating for each criterion was determined by applying the two-step RAND/University of California at Los Angeles Appropriateness Method. 25 In the first step, the existence of disagreement is determined by calculating the value of interpercentile range (IPR), or the range of responses that falls between the 70th and 30th percentiles, and comparing it with the value of the IPR adjusted for symmetry (IPRAS), which is a measure of dispersion for asymmetric distributions. If the IPR is greater than the IPRAS, it is an indicator of disagreement among participants. 25, 26 The median value was then used to determine whether the panel considered each criterion to be valid, invalid, or of uncertain validity. A median score between 7 and 9 indicated that a criterion was valid, a median score between 4 and 6 indicated uncertain validity, and a median score of 1 to 3 indicated that the criterion was invalid.
Differences in means between Round 3 and Round 1 responses were tested for, and none were found (analysis not shown). Therefore, to ensure that all data were used in the analysis, Round 1 responses of the experts who could not participate in Round 3 were combined with Round 3 responses of those who contributed to all rounds in tabulating the final ratings (Table S2) . 19, 27 Finally, for criteria that the e-Delphi panel deemed valid, mean scores were calculated, and the criteria were ranked from high to low to determine the top 25 criteria to be discussed during the second webinar to determine their relevance in the U.S. NH context.
RESULTS
Of the 22 invited experts, 17 participated (response rate 77%) in Round 1, 15 (88%) of whom participated in Round 2 and 11 (65%) in Round 3 ( Figure S2 ). Five (30%) of the 17 participants were primarily pharmacists, five (30%) were nurses, four (24%) were researchers, and three (18%) were physicians. Nine (53%) participants were principally employed at academic medical centers, seven (41%) at long-term care facilities, and one at a government agency (Table 1) . Twelve panel members attended the first webinar, and six attended the second. Table 2 shows the final list of the most highly rated STOPP/START criteria according to the standards of relevance for the U.S. NH setting, measurability with data available in NH electronic databases, and validity. In Phase 1 of this study, 61 of 114 STOPP/START criteria were deemed to be hard to measure. (See full list of criteria and ratings in Table S2 .) Requiring laboratory test results was the main reason for deeming a criterion infeasible to measure. Of the remaining 52 criteria, the e-Delphi panel rated 48 as valid (no disagreement and median score between 7 and 9), with only four criteria receiving an uncertain validity rating (Table S2) .
Participants in the first webinar elected to eliminate any criterion deemed to be of uncertain validity (four criteria). During the second webinar, the panel approved the top 25 valid criteria with the highest mean rating as a relevant and broadly useful subset to be applied in U.S. NHs. One additional criterion was excluded as a duplicate, resulting in a final list of 24 criteria (Table 2) . Twenty-two of the highest-rated criteria came from the STOPP list of potentially inappropriate medications. Only the criteria recommending pneumococcal vaccine at least once after age 65 according to national guidelines and seasonal flu vaccine annually from the START criteria of potential prescribing omissions received a rating high enough to be in the top 25 of the rankings. Medications used for treating the central nervous system accounted for the largest category of highly rated criteria (8/24).
DISCUSSION
To the knowledge of the authors, this is the first assessment of relevance, measurability, and validity of the STOPP/START criteria in the U.S. NH setting. The e-Delphi expert panel identified 24 criteria (22 STOPP, 2 START) with strong consensus on their potential for improving medication prescribing in the U.S. NH setting. Experts agreed on the validity of the STOPP/START criteria and relevance to the target population; a greater challenge was the feasibility of applying the criteria to the data elements available in electronic NH databases. Nearly half of the original STOPP/START criteria required individuallevel information from laboratory testing or physical assessment, which are generally not reliably captured outside the medical record. This study has a number of limitations. As with all research using the Delphi approach, the consensus decisions are linked to panel expertise. First, although the panel was diverse and included nurses, pharmacists, physicians, and researchers with NH expertise, a panel with a different range of NH expertise might have come to a different consensus decision. Second, not all participants answered Round 3 questions because of time constraints, although even with attrition, the panel was larger than nine people-the panel size that the RAND/UCLA Appropriateness Method recommends. Third, although attrition is not common in in-person panels, a 65% participation rate is adequate for online Delphi panels, which often have less than 50% participation rates. 28, 29 Nevertheless, this list of medication use criteria offers an evidence-based, consensus-generated tool that is uniquely tailored to the NH population of older U.S. adults. A comparison of the modified STOPP/START list with the 2015 version of the American Geriatrics Society (AGS) Beers criteria of potentially inappropriate prescribing in community-dwelling older adults shows substantial overlap and some differences (Table S3) . 12 The modified STOPP/START list includes 17 criteria that are also in the AGS Beers Criteria. The five unique STOPP criteria were systemic corticosteroids instead of inhaled corticosteroids with chronic obstructive pulmonary disease, proton pump inhibitors for longer than 8 weeks, antimuscarinic drugs with chronic prostatism, metformin with end-stage renal disease or dialysis, and oral elemental iron doses of more than 200 mg/d. The START criteria are also unique because there are no other broad-based medication use tools for recommending initiation of therapy in older adults. This modified STOPP/START list includes criteria for the important clinical care domains of initiating annual influenza vaccinations and the pneumococcal vaccination at least once in individuals aged 65 and older. Lastly, the assessment of measurement feasibility with information captured in widely used electronic NH databases has created a broadly useful subset of STOPP/START prescribing indicators. In summary, this study offers an assessment of the STOPP/START criteria in terms of validity, relevance to the U.S. NH setting, and measurement feasibility. Using the e-Delphi method, a panel of NH experts identified 24 criteria with strong consensus on the potential for improving medication prescribing in the U.S. NH setting. The formulation of expert-led, consensus-driven criteria on appropriate medication use is a developing area in LTC research. The originators of the STOPP/START criteria are convening their own Delphi panel of physicians and pharmacists to create a set of potentially inappropriate prescribing criteria for very frail older adults with less than 1 year to live. Future research should also validate the clinical impact on health outcomes in the NH population. We hope our adapted criteria are a useful tool for improving the overuse of potentially inappropriate medications and the underuse of potentially beneficial medications in older NH residents.
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